The Therapeutic Potential Of UC-MSCs Stem Cell Interventions for heart failure (HF) Recovery
Almost every year, in research, cardiovascular diseases emerge as one of the most studied ailments. heart failure (HF) becomes one of the most fatal as it leads to reduced life expectancy. Patients also suffer from severe fatigue and chronic difficulty in breathing. Patients suffering from HF usually become extremely active patients, and are usually admitted many times. Families of patients suffering from HF also suffer greatly from the burden HF places on them. The recovery of patients suffering from this affliction is becoming an urgent problem that needs to be solved. Current methods of managing them do not involve the resolution of the issues which have resulted in the destruction of the heart cells; the methods mainly involve the treatment of the symptoms. To overcome this, the clinicians begin to look at advanced Stem Cell therapies, specifically UC-MSCs, which are still in the early stages of development, as the treatment of the heart cells.
1.Disease Mechanism
One of the important cellular processes that occur in heart failure (HF) is the extensive death of myocardial cells. With ischemia and with chronic pressure overloads that are in the range of a few days, thousands to millions of heart cells may be lost permanently. The remaining tissue that is injured goes through a process of fibrosis which turns relatively flexible muscle tissue into highly inflexible scar-like fibrous collagen tissue. This scar formation processes greatly impede the ability of the heart ventricles to contract, and the formation of a lot of blood in the heart chambers and the lungs exacerbates the problems. It leads to the systemic distribution of the body’s internal organs the oxygen that is necessary. Without true cellular regeneration myocardial infarction as a clinical diagnosis will continue to aggregate and eventually will cause death to the human body. The important regenerative process that is also essential for the human heart is the use of externally supplied Stem Cell biological materials, such as UC-MSCs. The treatment of the heart cells is usually aimed at the cellular components of the structure that is to be restored.
- Limitations of Traditional Treatments
While some clinical guidelines recommend the use of β-blockers and enzyme inhibitors, the rest of the guidelines do not include any form of drug therapy. These agents optimize cardiac work and rest by lowering systemic arterial pressure or by reducing the heart rate to a baseline value. The effect of these agents is exacerbated by the use of diuretics, as they make the kidneys remove excess intra-vascular and extra-vascular fluid, which alleviates the degree of pulmonary congestion. Cardiac devices strive to improve the asynchrony of contraction of the diseased ventricles. Unfortunately, these interventions do not lead to the replacement of the permanent loss of cardiomyocytes and, at best, lead to an extension of the duration of the centipede’s demise, which is a very terminal condition. Organ transplantation is the last resort, but unrealistic due to the global shortage of organ donors. The evident and realistic limit to traditional heart failure (HF) therapy highlights the need for the development of new and better regenerative Stem Cell therapies using UC-MSCs. The new focus of clinical research is on the development of new techniques to restore the architecture of failing hearts.
- Justification Of Cell Therapy
Prominent researchers advocate regenerative therapy as an effective method for complex tissue regeneration. For example, when used as an agent for biological therapy for heart failure (HF), it uses several complex multipronged mechanisms. The UC-MSCs (Umbilical Cord – Mesenchymal Stem Cells) are most notable as they actively secrete a powerful and positively bioactive regenerative mixture of paracrine factors which bioactivity suppresses an adverse immuno-response and reduces the negative inflammation of the myocardium and failing heart. Additionally, they bioactivity encourage angiogenesis (the natural source creation of new blood vessels for the oxygen starving heart tissue) and control the adverse apoptosis (cell death) of cardiomyocytes, thus, preventing further cardiomyocyte deaths. Patients experience substantial improvements in the elasticity of the ventricular wall, due to the unique proprietary fibrosis-halt method used for control of progressive fibrosis, whereby, patients present with substantial improvements in the elastic capacity of the ventricles. The units used in Stem Cell therapy retain the unique immunomodulatory proprietary offerings which make the procedure safe for allogeneic transplant with minor immuno-response rejection issues.
- Prospects In Thailand
Thailand has rapidly become a center of cutting-edge regenerative medicine for cardiology, particularly for heart failure (HF). The country has state-of-the-art bio-medical research infrastructures and researchers who specialize in cell therapy. With the development and licensing of local Stem Cell therapy utilizing UC-MSCs, patients will now have reduced costs and local Stem Cell therapy will now provide reduced costs to patients, who previously needed to travel abroad for expensive treatment. The country has the ability to develop domestic regulations concerning management of local Stem Cell therapy. The safe local supply chain will ensure the vulnerable community has uninterrupted access to previously described therapy. This will ensure the national healthcare system will integrate with these advanced therapies and will provide prolonged service as an international healthcare system.